Molecular Testing - PT. RAFA


Molecular Testing

 Molecular Testing

Molecular Testing

Randox Molecular Diagnostics (MDx) offers a range of Molecular Arrays and assay formats, providing diagnostic, prognostic and predictive solutions for a range of conditions including sexually transmitted infection, respiratory infection, coronary heart disease (CHD), familial hypercholesterolemia and colorectal cancer with many more applications currently in development.

  • Array formats include SNP genotyping, gene expression, mutation detection and pathogen detection
  • Our unique multiplexing technique provides a complete patient profile from a single sample
  • Biochip Array Technology provides unrivalled cost, time and labour saving testing
  • Consolidate immunoassay and molecular diagnostics onto a single platform with the Evidence Investigator benchtop biochip analyser

STI Multiplex Array

The Randox STI multiplex array rapidly screens for the presence of 10 different STIs simultaneously from one patient sample. The simultaneous detection of these infections provides a comprehensive profile for each patient enabling the clinician to decide on the best treatment options, decreasing antibiotic misuse and the risk of the infection spreading.


The KRAS, BRAF, PIK3CA Array allows the clinician to simultaneously detect important mutations in the KRAS, BRAF and PIK3CA genes, enabling the appropriate selection of metastatic CRC patients for therapy.

Cardiac Risk Prediction Array

The Cardiac Risk Prediction Array provides simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment. Combining genotype information with common risk factors could allow accurate classification of patients and preventative therapies and lifestyle advice targeted to those who require it most.

Familial Hypercholesterolemia (FH) Array

The Randox FH Array provides rapid simultaneous detection of mutations within the LDLR, ApoB and PCSK9 genes. FH is a genetic disorder of lipoprotein metabolism characterised by high LDL levels and early onset of cardiovascular disease.